Results 81 to 90 of about 17,285 (228)
New oxadiazole derivatives of isonicotinohydrazide in the search for antimicrobial agents: Synthesis and in vitro evaluation [PDF]
Journal of the Serbian Chemical Society, 2012 Structural modification of the front line antitubercular drug isoniazid provide a lipophilic adaptations of the drug in which hydrazide moiety of isoniazid is replaced by 1,3,4-oxadiazole heterocycles to eliminate in-vivo acetylation by arylamine N ...
Malhotra Manav +3 more
doaj +1 more source
Pseudomonas as Versatile Aromatics Cell Factory
Biotechnology Journal, Volume 15, Issue 11, November 2020., 2020 This review highlights strategies and achievements regarding the microbial production of aromatics and derivatives from renewable substrates using Pseudomonas as whole‐cell biocatalyst. This includes the de novo biosynthesis and biotransformation of aromatics to other valuable chemicals.
Tobias Schwanemann +3 more
wiley +1 more source
Molecular Pharmacology, 2020 Arylamine N-acetyltransferase 1 (NAT1) is a phase II xenobiotic-metabolizing enzyme that also has a role in cancer cell growth and metabolism. Recently, it was reported that NAT1 undergoes lysine acetylation, an important post-translational modification ...
N. Butcher, Rachel Burow, R. Minchin
semanticscholar +1 more source
Effect of gene-gene and gene-environment interactions associated with antituberculosis drug-induced hepatotoxicity [PDF]
, 2017 This study evaluated the association between environmental factors and genetic variations in enzymes that metabolize antituberculosis (anti-TB) drugs [arylamine N-acetyltransferase 2, cytochrome P450 2E1 (CYP2E1), glutathione S-transferase theta 1 (GSTT1)
Aidar, O. +10 more
core +1 more source
Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay [PDF]
, 2013 Objectives: Lead antituberculosis (anti-TB) molecules with novel mechanisms of action are urgently required to fuel the anti-TB drug discovery pipeline.
Bhakta, Sanjib +9 more
core +1 more source
Frontiers in Pharmacology, 2022 N-acetyltransferase 1 (NAT1) is a xenobiotic metabolizing enzyme that uses acetyl coenzyme A (AcCoA) as a cofactor for N-acetylation of many carcinogens including aromatic amines and alkylanilines. NAT1 is characterized by single nucleotide polymorphisms
Mariam R. Habil +2 more
doaj +1 more source
Synergism between the N-acetyltransferase 2 gene and oxidant exposure increases the risk of idiopathic male infertility [PDF]
, 2014 N-acetyltransferase (NAT2) is a phase-II xenobiotic-metabolizing enzyme participating in the detoxification of toxic arylamines, aromatic amines and hydrazines.
Alexander V Ataman +5 more
core +1 more source
NAT2 global landscape: Genetic diversity and acetylation statuses from a systematic review.
PLoS ONE, 2023 Arylamine N-acetyltransferase 2 has been related to drug side effects and cancer susceptibility; its protein structure and acetylation capacity results from the polymorphism's arrays on the NAT2 gene.
Jorge E Gutiérrez-Virgen +6 more
doaj +2 more sources
NAT2 gene polymorphism in bladder cancer: a study from North India
International Brazilian Journal of Urology, 2004 PURPOSE: This study was conducted to examine: 1) whether the NAT2 genotypes are risk factors for bladder cancer, 2) to study possible association of tobacco usage with NAT2 genotype of these patients.
Rama D. Mittal +2 more
doaj +1 more source
Journal of Infection in Developing Countries, 2012 Introduction: Arylamine N-acetyltransferase-2 (NAT-2) is a key human enzyme in drug detoxification and elimination. Mutations in NAT-2 affect the activity of anti-tuberculosis drugs and result in three different phenotypes: rapid (RA), intermediate (IA)
Julián Gabriel Chamorro +5 more
doaj +1 more source